Does BDNF rs6265 AG modify responses to sleep deprivation without proving impaired restorative sleep?

BDNF rs6265 AG (Val/Met) is best viewed as a possible, modest modifier of particular responses to sleep loss—not as a stand-alone explanation for poor restorative sleep.

Neurobehavioral effects during sleep deprivation

• Small experimental studies suggest task-specific differences. After 20 hours awake in a 30-hour wakefulness protocol, Val/Met participants showed more Stroop response-inhibition errors and greater response-time costs, especially during the biological night. Other work reported better verbal 2-back accuracy in Val/Val participants and a small genotype interaction for vigilance-task speed.
• These findings do not support a broad, reliable vulnerability phenotype. In a 40-hour deprivation study, genotype did not significantly modify deterioration in psychomotor-vigilance response stability or subjective sleepiness. Sustained attention, sleepiness, and wellbeing have not been consistently genotype-dependent, while a simulated night-shift study found greater vigilance slowing and lapses among Met carriers.

Sleep physiology and restorative sleep

• Val/Met status has moderate mechanistic support for altered deep-sleep architecture: a small human sleep-laboratory study found lower NREM slow-wave activity and less stage-4 sleep in Val/Met carriers than Val/Val participants.
• Slow-wave activity and deep NREM sleep are relevant to restorative processes, so these results provide a biologically plausible pathway. Yet the same study found no genotype difference in subjective sleepiness or wellbeing, and self-reported sleep-quality findings were not significant. Thus, altered physiology does not establish the clinical symptom of persistent unrefreshing sleep.

Clinical implications

• Sleep complaints should be assessed clinically rather than inferred from rs6265 status: sleep opportunity and timing, daytime consequences, insomnia, sleep-disordered breathing, restless legs syndrome, mood, pain, medications/substances, medical illness, and menopausal symptoms are relevant considerations. A 7–14-day sleep diary and validated symptom measures are more informative than genotype alone.

Bottom line

• BDNF rs6265 AG is a plausible but preliminary modifier of selected cognitive effects of sleep deprivation and may be associated with reduced deep NREM sleep; it is not a validated independent marker of impaired restorative sleep.